Introduction: In the realm of targeted cancer therapy, precision is paramount. One compound that epitomizes this precision is Mc-Val-Cit-PABC-PNP, a chemical linker that plays a crucial role in the development of prodrugs, particularly antibody-drug conjugates (ADCs). This article delves into the intricacies of Mc-Val-Cit-PABC-PNP, exploring its chemical identity, health benefits, mechanism of action, and safety profile.
Chemical Name: The chemical name for Mc-Val-Cit-PABC-PNP is maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-p-nitrophenylalanine.
Molecular Formula: The molecular formula of Mc-Val-Cit-PABC-PNP is C41H50N8O10.
Formula Weight: The formula weight of Mc-Val-Cit-PABC-PNP is 810.9 g/mol.
CAS Number: The CAS number for Mc-Val-Cit-PABC-PNP is 159857-81-5.
Keywords and Synonyms: Upon researching the top ten keywords from Google, the following are closely associated with Mc-Val-Cit-PABC-PNP: targeted therapy, ADC linkers, prodrug activation, cancer treatment, precision medicine, cytotoxic delivery, enzymatic cleavage, therapeutic window, linker stability, and bioconjugation. Synonyms for this compound include its chemical name and the abbreviation of its components (MC-VC-PAB-PNP).
Competitive Products: Similar competitive products include other linkers used in ADCs, such as SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate), which is known for its non-cleavable stability, and SPDB (N-succinimidyl 4-(2-pyridyldithio)butanoate), which offers disulfide bond-based cleavability.
Health Benefits: The primary health benefit of Mc-Val-Cit-PABC-PNP is its targeted approach to cancer treatment. By facilitating the delivery of cytotoxic drugs directly to cancer cells, it minimizes the impact on healthy cells, potentially reducing the side effects commonly associated with chemotherapy.
Potential Effects: The potential effects of using Mc-Val-Cit-PABC-PNP in ADCs include improved efficacy of cancer drugs, reduced systemic toxicity, and enhanced patient quality of life during treatment.
Product Mechanism: Mc-Val-Cit-PABC-PNP functions by attaching a cytotoxic drug to an antibody specific to cancer cell antigens. The 'Val-Cit' dipeptide is stable in the bloodstream but cleaved by enzymes in cancer cells, releasing the drug directly at the tumor site.
Safety: The safety of Mc-Val-Cit-PABC-PNP is under continuous scrutiny, with ongoing research to ensure that its use in ADCs does not introduce unforeseen risks to patients.
Side Effects: Potential side effects are typically related to the cytotoxic agent used in the ADC rather than Mc-Val-Cit-PABC-PNP itself. However, any adverse effects are expected to be less severe due to the targeted nature of the therapy.
Dosing Information: Dosing of ADCs containing Mc-Val-Cit-PABC-PNP is highly specific and tailored to the individual patient, the type of cancer being treated, and the particular drug used in the conjugate.
Contraindications: Contraindications for the use of ADCs with Mc-Val-Cit-PABC-PNP depend on the associated drug and patient-specific factors such as allergies, pre-existing conditions, and other medications.
Conclusion: Mc-Val-Cit-PABC-PNP represents a significant advancement in the targeted treatment of cancer. Its role in ADCs exemplifies the progress being made in precision medicine, offering hope for more effective and less harmful cancer therapies. As research continues, the potential of Mc-Val-Cit-PABC-PNP to improve cancer treatment outcomes is immense, marking it as a compound of great interest in the field of medicinal chemistry.
